0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PSMA

PSMA

PSMA Molecule Information

Name:Glutamate carboxypeptidase II
Target Synonym:EC:3.4.17.21?GIG27?Glutamate carboxypeptidase II?NAALADase I?FOLH?Cell growth-inhibiting gene 27 protein?PSM?N-acetylated-alpha-linked acidic dipeptidase I?GCPII?Folylpoly-gamma-glutamate carboxypeptidase?Folate hydrolase 1?FOLH1?Pteroylpoly-Gamma-Glutama
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

PSMA Protein Product ListCompare or Buy

PSMA Part of Bioactivity data

PSA-H5264-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis of Human PSMA, Fc Tag binding to PSMA-CAR-293 cells transfected with anti-PSMA-scFv 2X105 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Human PSMA, Fc Tag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routinely tested).

PSA-HF244-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-PSMA CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human PSMA Protein, His Tag (Cat. No. PSA-HF244) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).

PSA-C5247-ELISA
Cynomolgus PSMA, His TagCynomolgus PSMA, His Tag (Cat. No. PSA-C5247) ELISA bioactivity

Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

PSA-C5247-MALS-HPLC
Cynomolgus PSMA, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) was more than 85% and the molecular weight of this protein is around 185-220 kDa verified by SEC-MALS.

Bioactivity-ELISA
Cynomolgus PSMA, His TagCynomolgus PSMA, His Tag (Cat. No. PSA-C5247) ELISA bioactivity

Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

PSMA Molecule Synonym Name

FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP

PSMA Molecule Background

Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily.  FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.

PSMA References

PSMA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capromab pendetide CYT-356; 111In CYT-356; lndium-CYT-356; Indium-111-CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms s:7:"Cytogen"; 1996-10-28 Prostatic Neoplasms Details
Gallium GA-68 PSMA-11 Ga-68-PSMA-11; Ga-68-PSMA Approved Radiomedix Gallium Ga 68 Psma-11 United States Prostatic Neoplasms s:37:"University Of California, Los Angeles"; 2020-12-01 Prostatic Neoplasms Details

PSMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AMG-160 AMG-160 Phase 1 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Neoplasms Details
MOR-209/ES414 APVO-414; MOR-209; ES-414 Phase 1 Clinical Emergent Prostatic Neoplasms Details
Gallium-68 PSMA-617 PSMA-617-[68Ga]; 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; 68Ga-DKFZ-PSMA -617 Clinical Deutsches Krebsforschungszentrum, University Of Heidelberg Prostatic Neoplasms Details
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
CC-1 CC-1 Phase 1 Clinical The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz Prostatic Neoplasms Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
HPN-424 HPN-424 Phase 2 Clinical Harpoon Therapeutics Prostatic Neoplasms Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase 1 Clinical Shanghai Bioray Laboratory Inc Prostatic Neoplasms Details
INO-5401 INO5401; INO-5401 Phase 2 Clinical Inovio Glioblastoma; Carcinoma, Transitional Cell Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
ATL-101 (ATLAB) J-591; MLN-591; huJ-591; muJ-591; 90Y-J591; MLN-591RL; 177Lu-J591; Lu-177-J591 Phase 2 Clinical Cornell University Prostatic Neoplasms Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Phase 2 Clinical Progenics Pharmaceuticals Inc Prostatic Neoplasms Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
Df-IA2BM-Zr-89 IAB2M; 89Zr-Df-IAB2M; Df-IA2BM-Zr-89; 64Cu-NODAGA-PSMA-Mb Phase 2 Clinical Imaginab Prostatic Neoplasms; Glioma Details
INO-5150 INO-5150 Phase 1 Clinical Inovio Prostatic Neoplasms Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6 Phase 2 Clinical Advanced Accelerator Applications Prostatic Neoplasms Details
[18F]DCFPyL Phase 3 Clinical Johns Hopkins University Carcinoma, Renal Cell; Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Clinical Advanced Accelerator Applications Prostatic Neoplasms Details

This web search service is supported by Google Inc.

totop